Physician profile
David E Trachtenbarg
NPI 1952318719
$25,642.31
in general payments reported to CMS, 2019-2025
34 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $510 · 2021: $2,934 · 2022: $578 · 2023: $2,389 · 2024: $810 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057 · Travel and Lodging: $1,398 · Education: $96.81 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.26 |
| Travel and Lodging | $1,397.89 |
| Education | $96.81 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16,213.95 | 2019-2025 | Wegovy, Ozempic |
| Novo Nordisk As | $2,598.43 | 2019 | |
| Biogen, INC. | $1,767.05 | 2023 | |
| Abbott Laboratories | $810.39 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Insulinx |
| Sanofi-Aventis U.S. LLC | $798.01 | 2019-2022 | |
| Dexcom, INC. | $394.40 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.01 | 2019-2022 | |
| Lilly USA, LLC | $303.30 | 2019-2021 | |
| Insulet Corporation | $286.05 | 2019-2024 | Omnipod |
| Amgen INC. | $235.48 | 2019-2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $221.87 | 2019-2022 | |
| Medtronic Minimed, INC. | $219.45 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $157.73 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $133.02 | 2019-2024 | Tymlos |
| Xeris Pharmaceuticals, INC. | $125.30 | 2021-2025 | Gvoke Hypopen, Recorlev |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $111.41 | 2019 | |
| Alexion Pharmaceuticals, INC. | $103.45 | 2019-2020 | |
| Medtronic, INC. | $97.59 | 2021-2024 | Intellis Adaptivestim, Minimed 780g |
| Senseonics, Incorporated | $92.00 | 2019 | |
| Companion Medical, INC. | $81.45 | 2019 | |
| Coloplast Corp | $73.57 | 2019 | |
| Corcept Therapeutics | $72.95 | 2019-2023 | Korlym |
| Shire North American Group INC | $60.72 | 2019 | |
| Abbvie INC. | $56.05 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $44.42 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $40.48 | 2020-2022 | |
| Valeritas, INC. | $36.18 | 2019 | |
| Zealand Pharma US, INC. | $24.23 | 2020 | |
| Kyowa Kirin, INC. | $24.19 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.12 | 2022 | |
| Amarin Pharma, INC. | $21.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.18 | 2021 | |
| Lifescan, INC. | $16.58 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Trachtenbarg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.